Stockscreener 앱 받기
1.795
0.28%
-0.005
전일 마감가:
$1.80
열려 있는:
$1.78
하루 거래량:
363.79K
Relative Volume:
0.18
시가총액:
$297.33M
수익:
$12.87M
순이익/손실:
$-114.34M
주가수익비율:
-2.0761
EPS:
-0.8646
순현금흐름:
$-79.23M
1주 성능:
+0.84%
1개월 성능:
-6.99%
6개월 성능:
-4.52%
1년 성능:
-26.73%
1일 변동 폭
$1.755
$1.845
1주일 범위
$1.70
$1.98
52주 변동 폭
$1.05
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
TSHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
1.79 | 297.33M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.57 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.97 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
628.63 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.89 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.36 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
What is Taysha Gene Therapies Inc (TSHA) Stock Return on Shareholders’ Capital? - Sete News
Taysha Gene Therapies’ (TSHA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Receives Market Outperform Rating from JMP Securities - Defense World
Understanding the Risks of Investing in Taysha Gene Therapies Inc (TSHA) - knoxdaily.com
Examining TSHA’s book value per share for the latest quarter - uspostnews.com
Taysha Gene Therapies Inc (NASDAQ: TSHA) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel
Geode Capital Management LLC Has $6.18 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Keeping an Eye on Taysha Gene Therapies Inc (TSHA) After Insider Trading Activity - knoxdaily.com
Taysha Gene Therapies Inc [TSHA] stock Initiated by BMO Capital Markets analyst, price target now $5 - dbtnews.com
Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st
Anchoring Your Portfolio: Is TSHA Stock a Safe Harbor? - investchronicle.com
What is going on with Taysha Gene Therapies Inc? Sentiment Analysis - uspostnews.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co. - Defense World
Vanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity - Seeking Alpha
Wellington Management Group LLP Raises Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Commonwealth Equity Services LLC Purchases 31,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages - The AM Reporter
AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors - The Manila Times
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Target Price from Brokerages - Defense World
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Expands Team: 822,000 Stock Options Awarded in Strategic Growth Move - Stock Titan
At $1.32 Price, Taysha Gene Therapies Inc (TSHA) Is Sitting And Waiting - stocksregister.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Tuesday - The AM Reporter
Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia
Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World
Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan
Alexandria Real Estate Equities, Inc. Elects Claire Aldridge, PhD, to Board of Directors - The Malaysian Reserve
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Yahoo Finance
TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks
Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Taysha Gene Therapies Reports 2024 Financial Results - TipRanks
Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
0.60%
자본화:
|
볼륨(24시간):